Bone Sarcoma Clinical Trial
Official title:
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
The main purpose of this study is to assess the short term and the long term side effects of proton beam radiation for pediatric bone and non-rhabdomyosarcoma soft tissue sarcomas.
- Participants will receive radiation treatments once per day, 5 days a week for a total of 4 to 6 weeks, depending on how much total dose the tumor requires. The radiation doctor will see the participant once each week to monitor and record any side effects they may have from radiation treatment. - A special device will be made for each participant to help them hold still during the treatment. This may either be a mask or foam cradle, depending on the area to be treated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05621668 -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
|
Phase 1 | |
| Not yet recruiting |
NCT05515068 -
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
|
||
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT05051059 -
Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients
|
N/A | |
| Recruiting |
NCT06129903 -
Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
|
N/A | |
| Completed |
NCT06202599 -
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
|
||
| Recruiting |
NCT04634227 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
|
Early Phase 1 | |
| Recruiting |
NCT03277924 -
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03462316 -
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
|
Phase 1 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
| Completed |
NCT02301039 -
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT06409013 -
Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
|
||
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04181970 -
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
|
||
| Completed |
NCT00525057 -
Dalteparin in Preventing DVT in Participants With Cancer
|
N/A | |
| Recruiting |
NCT04698785 -
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
|
Phase 2 | |
| Completed |
NCT01588522 -
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease
|
Phase 1 | |
| Terminated |
NCT03468075 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults
|
Phase 2 | |
| Recruiting |
NCT04616248 -
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
|
Phase 1 |